|
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
3
|
Resverlogix Corp.
|
Aug 22, 2018 07:08AM
|
|
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
|
5
|
Resverlogix Corp.
|
Jul 22, 2020 09:03AM
|
|
Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
5
|
Resverlogix Corp.
|
Jan 27, 2021 05:44PM
|
|
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism
|
5
|
Resverlogix Corp.
|
Jun 08, 2015 11:57AM
|
|
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
6
|
Resverlogix Corp.
|
Nov 02, 2020 07:46AM
|
|
Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 06, 2017 07:49PM
|
|
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
|
3
|
Resverlogix Corp.
|
Feb 03, 2020 09:19AM
|
|
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
|
3
|
Resverlogix Corp.
|
Oct 12, 2021 06:37PM
|
|
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Jul 25, 2017 09:48AM
|
|
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
7
|
Resverlogix Corp.
|
Jun 22, 2020 07:26AM
|
|
Resverlogix Publications, Presentations and Abstracts
|
10
|
Resverlogix Corp.
|
Sep 27, 2017 10:08AM
|
|
Resverlogix Provides Update on BETonMACE Phase 3 Trial
|
6
|
Resverlogix Corp.
|
Sep 16, 2019 08:44AM
|
|
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 10:56AM
|
|
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
2
|
Resverlogix Corp.
|
May 24, 2018 08:33AM
|
|
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
|
1
|
Resverlogix Corp.
|
Jan 23, 2017 11:17AM
|
|
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in PAH
|
3
|
Resverlogix Corp.
|
Mar 18, 2019 01:06PM
|
|
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
5
|
Resverlogix Corp.
|
Sep 04, 2018 08:54AM
|
|
Resverlogix presenting at Vascular Discovery 2019 next week
|
4
|
Resverlogix Corp.
|
May 10, 2019 04:49PM
|
|
Resverlogix presentation at European Meeting on Complement in Human Disease meeting
|
4
|
Resverlogix Corp.
|
Sep 08, 2017 03:01PM
|
|
Resverlogix poster from ASN 2016
|
4
|
Resverlogix Corp.
|
Nov 21, 2016 12:57PM
|
